EMA Recommends Extension of Indications for Ribociclib to Include Use in Patients with Early Breast Cancer By Ogkologos - November 5, 2024 658 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with early breast cancer at high risk of recurrence Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR ENLACE Study Explores Colorectal Cancer in Hispanic and Latino People October 18, 2023 EMA Recommends Granting a Marketing Authorisation for Capmatinib May 13, 2022 FOLFIRINOX Improves PFS Compared with Gemcitabine in Patients with Locally Advanced... May 26, 2025 Single Dose of HPV Vaccine Yields Long-Term Protection from Many Cancer-Causing... April 10, 2020 Load more HOT NEWS Study presents an AI-guided approach to target cancer antigens Pine Trees or COVID? FDA Approves Durvalumab for Locally Advanced or Metastatic Biliary Tract Cancer New on NCI Websites for July 2019
